Cerus Corp (Cerus) is a biomedical products company that develops and commercializes Intercept blood system and pathogen-protected blood components to enhance blood safety. The company operates through one reportable segment, blood safety. The company’s Intercept blood system targets and inactivates blood-borne pathogens such as HIV, West Nile, SARS, hepatitis B and C, bacteria, parasites, and white blood cells. It is also used for preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The R&D activities focus on improving its existing products and developing new products for blood safety. The company’s R&D also focuses on developing the red blood cell system in Europe, and its whole blood initiative in collaboration with US FDA. Cerus carries out R&D at its facilities in Concord, California, the US. The company focuses on licensure of the red blood cell system including the RedeS, ReCePI and other studies study for the treatment of chronic anemia, in vitro studies. It has entered into agreement with the Biomedical Advanced Research and Development Authority, or BARDA. Where the company receives funding from the BARDA to support the development of red blood cell system. In FY2022, the company spent US$64.1 million on its R&D, which as a percentage of revenue, stood at 34%. As of December 31, 2022, Cerus owned 10 issued or allowed US patents and 80 issued or allowed foreign patents related to the Intercept blood system.